You are here

Article Text

Article menu
Clinical and epidemiological research
Extended report
Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis
  1. Maria Juarez1,
  2. Holger Bang2,
  3. Friederike Hammar2,
  4. Ulf Reimer3,
  5. Bernard Dyke1,
  6. Ilfita Sahbudin1,
  7. Christopher D Buckley1,
  8. Benjamin Fisher1,
  9. Andrew Filer1,
  10. Karim Raza1,4
  1. 1Research Laboratories, Centre for Translational Inflammation Research, University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK
  2. 2Orgentec Diagnostika GmbH, Mainz, Germany
  3. 3JPT Peptide Technologies GmbH, Berlin, Germany
  4. 4Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK
  1. Correspondence to Professor Karim Raza, Research Laboratories, Centre for Translational Inflammation Research, University of Birmingham, Queen Elizabeth Hospital. Birmingham B15 2WB, UK; K.Raza{at}bham.ac.uk

Abstract

Objective To investigate serum antibody reactivity against a panel of post-translationally modified vimentin peptides (PTMPs) in patients with early inflammatory arthritis.

Methods A panel of PTMPs was developed. Microtitre plates were coated with peptides derived from vimentin that were identical in length and composition except at one amino acid that was changed to introduce one of three post-translational modifications (PTMs)—either a citrullinated, carbamylated or acetylated residue. Sera of 268 treatment-naive patients with early inflammatory arthritis and symptoms ≤3 months' duration were tested. Patients were assigned to one of three outcome categories at 18-month follow-up (rheumatoid arthritis (RA), persistent non-RA arthritis and resolving arthritis).

Results Antibodies against citrullinated, carbamylated and acetylated vimentin peptides were detected in the sera of patients with early inflammatory arthritis. The proportion of patients seropositive for all antibody types was significantly higher in the RA group than in the other groups. Anti cyclic citrullinated peptide (CCP)-positive patients with RA had higher numbers of peptides recognised and higher levels of antibodies against those peptides, representing a distinct profile compared with the other groups.

Conclusions We show for the first time that antibodies against acetylated vimentin are present in the sera of patients with early RA and confirm and extend previous observations regarding anticitrullinated and anticarbamylated antibodies.

  • Autoantibodies
  • Early Rheumatoid Arthritis
  • Rheumatoid Arthritis

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/annrheumdis-2014-206785

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Supplementary materials

    • Supplementary Data

      This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.